Navigation Links
Encision Reports 9.3% Revenue Increase in First Quarter Results
Date:7/28/2011

BOULDER, Colo., July 28, 2011 /PRNewswire/ -- Encision Inc. (Pink Sheets: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its first fiscal quarter ended June 30, 2011.

The Company recorded total revenue of $3.184 million, consisting of net product revenue of $2.833 million and net service revenue of $351 thousand, and had a net loss of $21,000 or $0.00 per share for the first quarter of fiscal year 2012. Total revenue represented a 9.3% increase from total revenue of $2.913 million for the first quarter of fiscal year 2011. The Company's net loss compared favorably to the $119,000 net loss, or $(0.02) per share for the first quarter of fiscal year 2011.

Gross profit margin, on total revenue, for the first quarter of fiscal year 2012 was 56% as compared to 63% for the first quarter of fiscal year 2011. The gross profit margin decrease from the first quarter of fiscal year 2011 was due to a planned manufacturing slowdown that resulted in higher product unit costs, principally of our disposable scissor inserts, and a slight increase, as a percentage of sales, of lower gross margin sales.

"We are pleased that our relationship with our strategic partners generated increased service revenue for us and enabled our total revenue to grow by 9.3% over our prior year's first quarter revenue," said Jack Serino, President and CEO of Encision Inc. "Our past efforts at expanding revenue opportunities through strategic partnerships has started to impact positively our revenue, as shown in our first quarter's revenue increase. These strategic partnership revenues complement our initiatives to regrow our AEM® business that was negatively impacted during the economic downturn and the resulting loss of business that we suffered."

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2011 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:
Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.comEncision Inc.Condensed Balance Sheets(Amounts in thousands)(Unaudited)June 30, 2011March 31, 2011ASSETSCash and cash equivalents$
88$
20Accounts receivable, net1,1591,160Inventories, net2,6932,604Prepaid expenses14474 Total current assets4,1843,958Equipment, net1,2781,169Patents, net267260Other assets1824 Total assets$ 5,747$ 5,411LIABILITIES AND SHAREHOLDERS' EQUITYAccounts payable$
755$
74Accrued compensation288261Other accrued liabilities312287Line of credit635435 Total current liabilities1,9901,657Common stock and additional paid-in capital19,80719,783Accumulated (deficit)(16,050)(16,029) Total shareholders' equity3,7573,754 Total liabilities and shareholders' equity$ 5,747$  5,411Encision Inc.Condensed Statements of Operations(Amounts in thousands, except per share information)(Unaudited)Three Months EndedJune 30, 2011June 30, 2010Net revenue: Product$ 2,833$ 2,864 Service35149Total revenue3,1842,913Cost of revenue: Product1,2611,023 Service14445Total cost of revenue1,4051,068Gross profit1,7791,845Operating expenses: Sales and marketing1,0371,186 General and administrative419396 Research and development331372Total operating expenses1,7871,954Operating loss(8)(109)Interest and other income (expense), net(13)(10)Loss before provision for income taxes(21)(119)Provision for income taxes––––Net loss$
(21)$   (119)Net loss per share—basic and diluted$   0.00$ (0.02)Basic  and diluted weighted average number of shares6,4556,455
'/>"/>

SOURCE Encision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision Reports Profitable Fourth Quarter and Fiscal Year 2011 Results
2. Encisions Active Electrode Monitoring Technology Recommended at Minimally Invasive Gynecology Congress
3. Encisions Technology Recognized as A Means to Eliminate Surgery Burns
4. Encision and HealthTrust Purchasing Group Sign Purchasing Agreement
5. Encision Reports Profitable Third Fiscal Quarter Results
6. Regeneron Reports Second Quarter 2011 Financial and Operating Results
7. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
8. Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook
9. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011
10. Covance Reports Second Quarter Revenue of $518 Million, GAAP EPS of $0.61, and Pro Forma EPS of $0.66
11. Hospira Reports Second-Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... Feb.8, 2016 Cardiovascular Surgery Devices - ... GlobalData,s Medical Devices sector report, "Cardiovascular Surgery Devices ... overview of Cardiovascular Surgery Devices currently in pipeline ... The report provides comprehensive information on the ... at various stages of development. The report reviews ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley ... into Canada to provide its range of unique and advantaged protective solutions ... City that will provide bilingual customer service and marketing support. A new distribution ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
Breaking Medicine News(10 mins):